Sign In
Buy CWBR
$0.410
+0 (+0%)
At Close: Apr 22, 2025
CohBar To Target COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with its Apelin Receptor Agonist Peptides
01:00pm, Tuesday, 05'th May 2020
CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that it has initiated test
Dividend Champions For May 2020
10:50am, Monday, 04'th May 2020
Monthly update of the Dividend Champions list. 29 companies declared higher dividends in the past month, with an average increase of 4.23% over their previous p
CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced its poster abstract for the Am
CohBar to Announce 2020 First Quarter Financial Results and Provide Business Update on May 14, 2020
01:00pm, Thursday, 30'th Apr 2020
CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will rel
Is CohBar, Inc. (NASDAQ:CWBR) A Volatile Stock?
01:21pm, Sunday, 19'th Apr 2020
Anyone researching CohBar, Inc. (NASDAQ:CWBR) might want to consider the historical volatility of the share price...
CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced acceptance of a late-break
CohBar Provides Update on CB4211 Phase 1b Study for NASH and Obesity
12:45pm, Monday, 30'th Mar 2020
CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that it is anticipating de
What Apple, Microsoft, GE and other U.S. companies are saying about the coronavirus outbreak
02:15pm, Sunday, 22'nd Mar 2020
The new coronavirus that was first identified late last year in Wuhan, China, is a dominant theme in the earnings releases and conference calls of S&P 500...
CohBar Reports Fourth Quarter 2019 Financial Results and Provides Business Update
08:02pm, Thursday, 12'th Mar 2020
MENLO PARK, Calif., March 12, 2020 -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic.
CohBar, Inc. to Host Earnings Call
07:00pm, Thursday, 12'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / CohBar, Inc. (NASDAQ:CWBR) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at 5:00 PM Eas
CohBar to Hold Investor Meetings at the ROTH Virtual Conference
12:30pm, Thursday, 12'th Mar 2020
CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will hold
Coronavirus update: 118,100 cases, 4,262 deaths, airlines cut capacity and some CEOs take pay cuts
07:14pm, Tuesday, 10'th Mar 2020
Airlines, hotels and cruise line operators that have relied on consumers and business professionals who have been spending freely on travel are again telling...
MA Coronavirus Cases Hit 92 As State Of Emergency Declared
04:26pm, Tuesday, 10'th Mar 2020
Massachusetts health officials said 70 of the coronavirus cases were traced to a Biogen conference in Boston in February.
American dream: fresh face scoops up Quadrant's APM in $1.5b deal
04:45am, Tuesday, 10'th Mar 2020
American private equity firm Madison Dearborn Partners has secured its first major Australian buyout.
CohBar to Announce 2019 Fourth Quarter Financial Results and Provide Business Update on March 12, 2020
09:30pm, Monday, 02'nd Mar 2020
CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases and extend healthy lifespan, announced today that the company w
